Psych Congress 2017

Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.

Results indicate there is an unmet need for better treatment to manage symptom burden in US adults with ADHD.

SHP465 MAS is a once-daily, extended-release oral agent for the treatment of ADHD that contains equal parts of 4 salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate.

Augmentation therapy for treatment-resistant major depressive disorder includes multiple options with different strengths and limitations.

The 6-month study examined the safety, efficacy, and tolerability of Aristada in patients with schizophrenia who had an inadequate response or intolerance to Invega Sustenna.

For patients with bipolar disorder and major depressive disorder, reduction in dose of antipsychotic medication could lead to an increased rate of hospitalization.

Recent changes in our understanding of autism are driving advances in diagnosis, evidence-based treatment, and ultimately patient outcomes.

Combination treatment may provide relief from the distinctive symptoms of severe, recurrent temper outbursts and persistent irritability.

Dr. Grant also acknowledged that while some patients are uncomfortable with the fact that medication doses for OCD are higher than they are for depression, those higher doses are crucial for symptomatic improvement.

Michael Thase, MD, discusses therapy options as well as side effect management for individuals with major depressive disorder.